Literature DB >> 17118230

Inflammation and diabetic nephropathy.

Carmen Mora, Juan F Navarro.   

Abstract

Diabetic nephropathy has become the main cause of renal failure, but unfortunately the intimate mechanisms leading to the development and progression of renal injury are not yet fully known. Activated innate immunity and inflammation are relevant factors in the pathogenesis of diabetes. Moreover, different inflammatory molecules, including chemokines, adhesion molecules, and proinflammatory cytokines, may be critical factors in the development of microvascular diabetic complications, including nephropathy. This new pathogenic perspective leads to important therapeutic considerations, with new pathogenic pathways becoming important therapeutic targets that can be translated into clinical treatments for diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118230     DOI: 10.1007/s11892-006-0080-1

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  77 in total

1.  Suppression of experimental systemic lupus erythematosus (SLE) in mice via TNF inhibition by an anti-TNFalpha monoclonal antibody and by pentoxiphylline.

Authors:  R Segal; M Dayan; H Zinger; E Mozes
Journal:  Lupus       Date:  2001       Impact factor: 2.911

2.  Plasma interleukin-6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes.

Authors:  J C Pickup; G D Chusney; S M Thomas; D Burt
Journal:  Life Sci       Date:  2000-06-08       Impact factor: 5.037

3.  Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice.

Authors:  Fiona Y Chow; David J Nikolic-Paterson; Elyce Ozols; Robert C Atkins; Gregory H Tesch
Journal:  J Am Soc Nephrol       Date:  2005-04-27       Impact factor: 10.121

4.  Pentoxifylline attenuates experimental mesangial proliferative glomerulonephritis.

Authors:  Y M Chen; C T Chien; M I Hu-Tsai; K D Wu; C C Tsai; M S Wu; T J Tsai
Journal:  Kidney Int       Date:  1999-09       Impact factor: 10.612

5.  Interleukin-6 gene polymorphism and insulin sensitivity.

Authors:  J M Fernández-Real; M Broch; J Vendrell; C Gutiérrez; R Casamitjana; M Pugeat; C Richart; W Ricart
Journal:  Diabetes       Date:  2000-03       Impact factor: 9.461

Review 6.  Leukocyte and endothelial cell adhesion molecules as targets for therapeutic interventions in inflammatory disease.

Authors:  Holger Ulbrich; Einar E Eriksson; Lennart Lindbom
Journal:  Trends Pharmacol Sci       Date:  2003-12       Impact factor: 14.819

7.  Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors.

Authors:  S Müller; S Martin; W Koenig; P Hanifi-Moghaddam; W Rathmann; B Haastert; G Giani; T Illig; B Thorand; H Kolb
Journal:  Diabetologia       Date:  2002-05-08       Impact factor: 10.122

8.  Pentoxifylline attenuated the renal disease progression in rats with remnant kidney.

Authors:  Shuei-Liong Lin; Yung-Ming Chen; Chiang-Ting Chien; Wen-Chih Chiang; Chien-Chen Tsai; Tun-Jun Tsai
Journal:  J Am Soc Nephrol       Date:  2002-12       Impact factor: 10.121

9.  Circulating monocyte chemoattractant protein-1 and early development of nephropathy in type 1 diabetes.

Authors:  Francesco Chiarelli; Francesco Cipollone; Angelika Mohn; Matteo Marini; Annalisa Iezzi; Maria Fazia; Stefano Tumini; Domenico De Cesare; Mariapina Pomilio; Sante D Pierdomenico; Mario Di Gioacchino; Franco Cuccurullo; Andrea Mezzetti
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

10.  Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study.

Authors:  Juan F Navarro; Carmen Mora; Mercedes Muros; Manuel Maca; Javier Garca
Journal:  Am J Kidney Dis       Date:  2003-08       Impact factor: 8.860

View more
  64 in total

1.  Aberrant expression of soluble co-stimulatory molecules and adhesion molecules in type 2 diabetic patients with nephropathy.

Authors:  C K Wong; Amy W Y Ho; Peter C Y Tong; C Y Yeung; Juliana C N Chan; Alice P S Kong; Christopher W K Lam
Journal:  J Clin Immunol       Date:  2007-11-17       Impact factor: 8.317

2.  Inhibition of macrophage migration inhibitory factor reduces diabetic nephropathy in type II diabetes mice.

Authors:  Zhigang Wang; Meng Wei; Meng Wang; Lei Chen; Hua Liu; Yi Ren; Kehui Shi; Hongli Jiang
Journal:  Inflammation       Date:  2014-12       Impact factor: 4.092

Review 3.  Inflammation in diabetic kidney disease.

Authors:  Patricia M García-García; María A Getino-Melián; Virginia Domínguez-Pimentel; Juan F Navarro-González
Journal:  World J Diabetes       Date:  2014-08-15

4.  Increased circulating cytokine levels in African American women with obesity and elevated HbA1c.

Authors:  Ariel Williams; Natasha Greene; K Kimbro
Journal:  Cytokine       Date:  2020-01-28       Impact factor: 3.861

5.  Expression of cholecystokinin-1 receptor is correlated with proteinuria in human diabetic nephropathy.

Authors:  Mingao Wang; Rujuan Xie; Ruichan Liu; Xibei Jia; Yushi Bao; Xiaomin Liu
Journal:  Endocrine       Date:  2012-03-07       Impact factor: 3.633

6.  The effects of ozone therapy on caspase pathways, TNF-α, and HIF-1α in diabetic nephropathy.

Authors:  Aydın Güçlü; Haydar Ali Erken; Gülten Erken; Yavuz Dodurga; Arzu Yay; Özge Özçoban; Hasan Şimşek; Aydın Akçılar; Fatma Emel Koçak
Journal:  Int Urol Nephrol       Date:  2015-11-27       Impact factor: 2.370

7.  Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it?

Authors:  Roger M Mason
Journal:  J Cell Commun Signal       Date:  2009-02-14       Impact factor: 5.782

Review 8.  Pentoxifylline for Diabetic Nephropathy: an Important Opportunity to Re-purpose an Old Drug?

Authors:  Shelly Bhanot; David J Leehey
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

Review 9.  Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge.

Authors:  Sebastian Martini; Felix Eichinger; Viji Nair; Matthias Kretzler
Journal:  Rev Endocr Metab Disord       Date:  2008-12       Impact factor: 6.514

10.  The effect of chronic candesartan therapy on the metabolic profile and renal tissue cytokine levels in the obese Zucker rat.

Authors:  Carolyn M Ecelbarger; Arjun Rash; Rajesh K Sinha; Swasti Tiwari
Journal:  Mediators Inflamm       Date:  2010-05-17       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.